Skip to main content
. 2018 Feb 16;41(5):2629–2639. doi: 10.3892/ijmm.2018.3501

Figure 5.

Figure 5

Effect of mesenchymal stem cells (MSCs) on survival rate, body weight and renal function. (A) Ten-week survival rates of the 3 groups: NC group, 100%; diabetic nephropathy (DN) group, 35.7%; DN-MSC group, 81.8% (*p=0.01). Data were analyzed by log-rank test. Renal function: (B) microalbumin (MAU) (mg/l), (C) albumin to creatinine ratio (ACR) (µg/μmol) and (D) blood urea nitrogen (BUN) (mM) were measured in serum and urine in the 3 groups at 4, 5, 8 and 10 weeks after diabetes onset. Renal function was significantly improved in the MSC-treated group compared with that noted in the DN group. Data are expressed as means ± SD of evaluations from each group. [*p<0.05 vs. normal group (NC); #p<0.05 vs. DN group].